Primary Objective: The purpose of this study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab SAR236553...
Esperion announced positive top-line results from the pivotal Phase III bempedoic acid / ezetimibe combination pill study (1002-053). This trial...